

Jonathan E Rosenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8443746/publications.pdf>

Version: 2024-02-01

208
papers

26,112
citations

20817

60
h-index

7160

153
g-index

217
all docs

217
docs citations

217
times ranked

25898
citing authors

#	ARTICLE	IF	CITATIONS
1	TGF β 2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <i>Nature</i> , 2018, 554, 544-548.	27.8	3,359
2	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2016, 387, 1909-1920.	13.7	3,077
3	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	21.4	2,702
4	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2017, 389, 67-76.	13.7	1,728
5	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 709-717.	1.6	829
6	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1590-1598.	10.7	594
7	Treatment of Patients With Metastatic Urothelial Cancer for Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 2432-2438.	1.6	514
8	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. <i>Cancer Discovery</i> , 2014, 4, 1140-1153.	9.4	506
9	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1125-1135.	27.0	473
10	Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2592-2600.	1.6	404
11	Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 181-186.	1.6	401
12	Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 2280-2285.	1.6	400
13	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. <i>Journal of Clinical Oncology</i> , 2018, 36, 1685-1694.	1.6	399
14	Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3743-3748.	1.6	381
15	Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. <i>Nature Genetics</i> , 2016, 48, 600-606.	21.4	352
16	Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens. <i>Journal of Clinical Oncology</i> , 2010, 28, 1850-1855.	1.6	340
17	A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2014, 32, 178-187.	2.6	302
18	Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib. <i>Cancer Discovery</i> , 2014, 4, 546-553.	9.4	266

#	ARTICLE	IF	CITATIONS
19	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. <i>European Urology</i> , 2017, 72, 952-959.	1.9	263
20	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. <i>Lancet Oncology</i> , The, 2011, 12, 211-214.	10.7	261
21	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. <i>PLoS Medicine</i> , 2017, 14, e1002309.	8.4	256
22	Clonal evolution of chemotherapy-resistant urothelial carcinoma. <i>Nature Genetics</i> , 2016, 48, 1490-1499.	21.4	250
23	High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. <i>Nature Medicine</i> , 2020, 26, 693-698.	30.7	250
24	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. <i>Journal of Clinical Oncology</i> , 2014, 32, 1889-1894.	1.6	229
25	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3610-3618.	7.0	225
26	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 525-537.	10.7	225
27	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
28	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations. <i>Cancer Discovery</i> , 2018, 8, 812-821.	9.4	206
29	Clinical Validation of Chemotherapy Response Biomarker <i>ERCC2</i> in Muscle-Invasive Urothelial Bladder Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 1094.	7.1	205
30	Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015, 68, 970-977.	1.9	202
31	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019, 37, 1608-1616.	1.6	185
32	Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1323-1333.	7.0	177
33	Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 507-512.	1.6	168
34	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 967-976.	7.0	164
35	Treatment Outcomes of Immune-Related Cutaneous Adverse Events. <i>Journal of Clinical Oncology</i> , 2019, 37, 2746-2758.	1.6	160
36	EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1041-1049.	1.6	159

#	ARTICLE	IF	CITATIONS
37	Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. <i>Cancer</i> , 2015, 121, 2586-2593.	4.1	155
38	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016, 48, 356-358.	21.4	143
39	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
40	Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. <i>Lancet Oncology</i> , 2010, 11, 861-870.	10.7	123
41	Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2015, 67, 198-201.	1.9	122
42	Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2021, 22, 872-882.	10.7	122
43	Synthetic Lethality in ATM-Deficient <i>RAD50</i> -Mutant Tumors Underlies Outlier Response to Cancer Therapy. <i>Cancer Discovery</i> , 2014, 4, 1014-1021.	9.4	114
44	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1949-1956.	1.6	110
45	Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. <i>European Urology</i> , 2013, 63, 717-723.	1.9	104
46	<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 977-988.	7.0	104
47	Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. <i>European Urology</i> , 2019, 75, 231-239.	1.9	104
48	Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 3145-3152.	2.8	99
49	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. <i>Nature Communications</i> , 2017, 8, 2193.	12.8	99
50	The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. <i>European Urology</i> , 2019, 75, 435-444.	1.9	97
51	Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes. <i>Cell Reports</i> , 2018, 23, 512-521.	6.4	90
52	Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 221-234.	27.6	89
53	The biology and rationale of targeting nectin-4 in urothelial carcinoma. <i>Nature Reviews Urology</i> , 2021, 18, 93-103.	3.8	89
54	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018, 24, 1965-1973.	7.0	85

#	ARTICLE	IF	CITATIONS
55	Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2013, 105, 499-503.	6.3	79
56	Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 441-441.	1.6	79
57	The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 5218-5226.	7.0	77
58	FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. <i>Cancer Medicine</i> , 2014, 3, 835-844.	2.8	76
59	Clinical Pathologic Stage Discrepancy in Bladder Cancer Patients Treated With Radical Cystectomy: Results From the National Cancer Data Base. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1048-1056.	0.8	71
60	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. , 2017, 5, 68.		68
61	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. <i>JAMA Oncology</i> , 2020, 6, 84.	7.1	66
62	The evolving understanding of microRNA in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 41.e31-41.e40.	1.6	65
63	Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12288-12294.	7.1	65
64	Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 80-89.	4.4	63
65	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 1873-1883.	7.0	63
66	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. <i>Journal of Clinical Oncology</i> , 2020, 38, 406-414.	1.6	60
67	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. <i>American Journal of Surgical Pathology</i> , 2019, 43, 920-927.	3.7	59
68	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>European Urology</i> , 2017, 71, 281-289.	1.9	56
69	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2016, 195, 277-282.	0.4	54
70	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	54
71	A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. <i>Cancer</i> , 2005, 103, 2035-2041.	4.1	52
72	Genomic characterization of response to chemoradiation in urothelial bladder cancer. <i>Cancer</i> , 2016, 122, 3715-3723.	4.1	50

#	ARTICLE	IF	CITATIONS
73	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. <i>Journal of Urology</i> , 2020, 204, 1173-1179.	0.4	47
74	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. <i>Scientific Reports</i> , 2016, 6, 27702.	3.3	46
75	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1312-1322.	1.6	42
76	<scp>HER2</scp> as a target in invasive urothelial carcinoma. <i>Cancer Medicine</i> , 2015, 4, 844-852.	2.8	41
77	Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 621-625.	2.5	40
78	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. <i>Cancer</i> , 2020, 126, 2597-2606.	4.1	39
79	Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. <i>Cancer</i> , 2019, 125, 533-540.	4.1	38
80	EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4505-4505.	1.6	38
81	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. <i>Nature Communications</i> , 2020, 11, 1975.	12.8	37
82	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. <i>Nature Communications</i> , 2022, 13, 1935.	12.8	37
83	Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium. <i>Journal of Clinical Oncology</i> , 2009, 27, 2772-2778.	1.6	36
84	The Safety and Efficacy of Single-Agent Pemetrexed in Platinum-Resistant Advanced Urothelial Carcinoma: A Large Single-Institution Experience. <i>Oncologist</i> , 2015, 20, 508-515.	3.7	36
85	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2016, 195, 1684-1689.	0.4	36
86	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. <i>European Urology</i> , 2018, 73, 462-468.	1.9	36
87	Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. <i>Oncologist</i> , 2022, 27, e223-e232.	3.7	36
88	Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 352-359.	1.9	34
89	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). <i>British Journal of Cancer</i> , 2018, 118, 1434-1441.	6.4	34
90	Optimal Treatment for Metastatic Bladder Cancer. <i>Current Oncology Reports</i> , 2014, 16, 404.	4.0	32

#	ARTICLE	IF	CITATIONS
91	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. <i>Cancer</i> , 2019, 125, 3155-3163.	4.1	32
92	Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 387-394.	1.9	32
93	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 165-202.	0.4	30
94	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. <i>European Urology Focus</i> , 2019, 5, 201-204.	3.1	30
95	Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210. <i>Journal of Clinical Oncology</i> , 2018, 36, 4523-4523.	1.6	29
96	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 707-712.	6.4	28
97	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 130-137.	1.9	27
98	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. <i>Human Pathology</i> , 2018, 77, 63-69.	2.0	27
99	SnapShot: Bladder Cancer. <i>Cancer Cell</i> , 2018, 34, 350-350.e1.	16.8	27
100	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 200, 1207-1214.	0.4	26
101	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021, 13, 96.	8.2	26
102	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). <i>Journal of Clinical Oncology</i> , 2021, 39, 2486-2496.	1.6	26
103	Treatment Decision Making in Patients with Bladder Cancer. <i>Bladder Cancer</i> , 2015, 1, 151-158.	0.4	25
104	DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. <i>BMC Cancer</i> , 2015, 15, 242.	2.6	25
105	The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. <i>Cancer</i> , 2016, 122, 712-721.	4.1	25
106	Identification of Nine Genomic Regions of Amplification in Urothelial Carcinoma, Correlation with Stage, and Potential Prognostic and Therapeutic Value. <i>PLoS ONE</i> , 2013, 8, e60927.	2.5	24
107	Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). <i>Journal of Clinical Oncology</i> , 2023, 41, 43-53.	1.6	24
108	Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?. <i>European Journal of Cancer</i> , 2016, 53, 96-104.	2.8	23

#	ARTICLE	IF	CITATIONS
109	The emerging role of antibody-drug conjugates in urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 551-561.	2.4	23
110	Fundamental immune oncogenicity trade-offs define driver mutation fitness. <i>Nature</i> , 2022, 606, 172-179.	27.8	23
111	Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. <i>Acta Oncologica</i> , 2018, 57, 491-497.	1.8	22
112	A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 106-106.	1.6	22
113	Management of Treatment-Related Toxicity with Targeted Therapies for Renal Cell Carcinoma: Evidence-Based Practice and Best Practices. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 893-915.	2.2	21
114	Molecular targets on the horizon for kidney and urothelial cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 557-570.	27.6	21
115	First-Line Treatment and Prognostic Factors of Metastatic Bladder Cancer for Platinum-Eligible Patients. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 319-328.	2.2	21
116	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 907-915.	1.9	21
117	Antibody-Drug Conjugates in Urothelial Carcinomas. <i>Current Oncology Reports</i> , 2020, 22, 13.	4.0	21
118	Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches. <i>Frontiers in Pharmacology</i> , 2013, 4, 3.	3.5	20
119	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. <i>Advances in Anatomic Pathology</i> , 2021, 28, 196-208.	4.3	20
120	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 95-105.	2.2	19
121	Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2011-2022.	7.0	19
122	EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 394-394.	1.6	19
123	Utility of Routine Preoperative ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. <i>Journal of Urology</i> , 2020, 204, 254-259.	0.4	19
124	Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 377-377.	1.6	19
125	Nivolumab for the treatment of urothelial cancers. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 215-221.	2.4	18
126	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3 altered Advanced/Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 916-924.	1.9	18

#	ARTICLE	IF	CITATIONS
127	Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 410-420.	1.9	17
128	The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 755-760.	1.7	17
129	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. <i>Cancer</i> , 2016, 122, 2389-2398.	4.1	16
130	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
131	Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. <i>PLoS ONE</i> , 2015, 10, e0124711.	2.5	16
132	Actionable mutations in muscle-invasive bladder cancer. <i>Current Opinion in Urology</i> , 2013, 23, 472-478.	1.8	15
133	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1997-2010.	7.0	15
134	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e961-e967.	1.9	14
135	A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor. <i>PLoS ONE</i> , 2018, 13, e0208422.	2.5	14
136	A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. <i>Cancer</i> , 2020, 126, 4532-4544.	4.1	14
137	Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 430-438.	0.7	14
138	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 1214-1221.	6.4	14
139	DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4509-4509.	1.6	14
140	Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063). <i>Bladder Cancer</i> , 2017, 3, 113-119.	0.4	13
141	Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 863-873.	3.1	13
142	Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience. <i>Journal of Urology</i> , 2020, 204, 677-684.	0.4	13
143	Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer. <i>Cancer</i> , 2013, 119, 1994-1998.	4.1	12
144	Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. <i>Cancer Medicine</i> , 2017, 6, 186-194.	2.8	12

#	ARTICLE	IF	CITATIONS
145	Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e483-e490.	1.9	12
146	Bladder cancer: modeling and translation. <i>Genes and Development</i> , 2009, 23, 655-659.	5.9	11
147	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 53-64.	1.6	11
148	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2â€“4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. <i>European Urology Oncology</i> , 2019, 2, 248-256.	5.4	11
149	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. <i>European Urology Oncology</i> , 2020, 3, 671-679.	5.4	11
150	The Role of Genomics in the Management of Advanced Bladder Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 319.	3.0	10
151	Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma. <i>Urologic Clinics of North America</i> , 2018, 45, 287-295.	1.8	10
152	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. <i>Oncologist</i> , 2019, 24, 1348-1355.	3.7	10
153	Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2021, 44, 248-253.	2.4	10
154	A phase II trial of durvalumab and tremelimumab in metastatic, nonâ€“urothelial carcinoma of the urinary tract. <i>Cancer Medicine</i> , 2021, 10, 1074-1083.	2.8	10
155	Cancer predisposing germline mutations in patients (pts) with urothelial cancer (UC) of the renal pelvis (R-P), ureter (U) and bladder (B).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4510-4510.	1.6	10
156	Identification of ALK Gene Alterations in Urothelial Carcinoma. <i>PLoS ONE</i> , 2014, 9, e103325.	2.5	9
157	Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. <i>Cancer</i> , 2015, 121, 2603-2611.	4.1	9
158	Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4539-4539.	1.6	9
159	Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4517-4517.	1.6	9
160	Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. <i>BJU International</i> , 2022, 129, 463-469.	2.5	9
161	Developing Precision Medicine for Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 633-653.	2.2	9
162	Suggestions for Regulatory Agency Approval of Second-Line Systemic Therapy for Metastatic Transitional Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2010, 28, e205-e207.	1.6	8

#	ARTICLE	IF	CITATIONS
163	Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma. <i>Bladder Cancer</i> , 2016, 2, 111-117.	0.4	8
164	Circulating biomarkers to guide systemic therapy for urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 502-509.	1.6	8
165	EMA and FDA prune the checkpoint inhibitor treatment landscape. <i>Nature Reviews Urology</i> , 2018, 15, 596-597.	3.8	8
166	Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. <i>JAMA Oncology</i> , 2019, 5, 1790.	7.1	8
167	EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4593-TPS4593.	1.6	8
168	Novel molecular targets for urothelial carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 515-525.	3.4	7
169	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e113-e120.	1.9	7
170	Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): Assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND.. <i>Journal of Clinical Oncology</i> , 2014, 32, 355-355.	1.6	7
171	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. <i>JCO Precision Oncology</i> , 2022, , .	3.0	6
172	Hormonal Therapy or External-Beam Radiation With Brachytherapy and the Risk of Death From Prostate Cancer in Men With Intermediate Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 21-25.	1.9	5
173	Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 250-256.	1.9	5
174	<i>NECTIN4</i> Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibody-Drug Conjugate. <i>Clinical Cancer Research</i> , 2021, 27, 4950-4952.	7.0	5
175	EV-103 study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS532-TPS532.	1.6	5
176	Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 431-441.	1.9	5
177	Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014 . <i>European Urology</i> , 2015, 68, e31-e32.	1.9	4
178	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e81-e90.	1.9	4
179	MCL1 and DEDD Promote Urothelial Carcinoma Progression. <i>Molecular Cancer Research</i> , 2019, 17, 1294-1304.	3.4	4
180	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1084-1091.	3.1	4

#	ARTICLE	IF	CITATIONS
181	Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4267-4277.	7.0	4
182	Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. <i>Bladder Cancer</i> , 2016, 2, 203-213.	0.4	3
183	Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e161-e167.	1.9	3
184	Refining existing knowledge and management of bladder cancer. <i>Nature Reviews Urology</i> , 2019, 16, 75-76.	3.8	3
185	Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 205, 414-419.	0.4	3
186	Dermatologic infections in cancer patients treated with checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1528-1536.	1.2	3
187	Beyond Chemotherapy and Checkpoint Inhibitors: Weighing the Risks and Benefits of the Novel Therapies for Metastatic Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01430.	1.6	3
188	Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 4510-4510.	1.6	3
189	Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 185-192.	1.9	2
190	Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience. <i>Journal of Clinical Oncology</i> , 2021, 39, 4526-4526.	1.6	2
191	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e178-e183.	1.9	2
192	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. <i>Bladder Cancer</i> , 2021, 7, 1-6.	0.4	2
193	Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC). <i>Journal of Clinical Oncology</i> , 2012, 30, 4525-4525.	1.6	2
194	Efficacy of single-agent pemetrexed in platinum refractory metastatic urothelial cancer (mUC). <i>Journal of Clinical Oncology</i> , 2014, 32, 322-322.	1.6	2
195	What is the current status of second-line chemotherapy for castration-resistant prostate cancer?. <i>Nature Reviews Urology</i> , 2008, 5, 650-651.	1.4	1
196	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. <i>Journal of Clinical Oncology</i> , 2014, 32, 4171-4172.	1.6	1
197	Reply to S. Zhang et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 3057-3058.	1.6	1
198	A comprehensive Memorial Sloan Kettering Cancer Center real-world data model: Core clinical data elements. <i>Journal of Clinical Oncology</i> , 2021, 39, e18755-e18755.	1.6	1

#	ARTICLE	IF	CITATIONS
199	FGFR3 protein expression and gene mutation in primary and metastatic urothelial carcinoma (UC) tumors.. Journal of Clinical Oncology, 2012, 30, 4577-4577.	1.6	1
200	PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target?. Journal of Clinical Oncology, 2012, 30, 4582-4582.	1.6	1
201	The Cost of Enfortumab Vedotin Wastage Due to Vial Sizeâ€”A Real-World Analysis. Cancers, 2021, 13, 5977.	3.7	1
202	Reply to S. Zhang. Journal of Clinical Oncology, 0, , .	1.6	1
203	Lessons learned from exceptional responders. Expert Review of Precision Medicine and Drug Development, 2019, 4, 73-80.	0.7	0
204	Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016 . European Urology, 2021, 79, e56-e57.	1.9	0
205	Impact of first-line platinum therapy on survival in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium (TCCU) treated with vinflunine.. Journal of Clinical Oncology, 2012, 30, e15007-e15007.	1.6	0
206	External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy.. Journal of Clinical Oncology, 2012, 30, 4592-4592.	1.6	0
207	Reply by Authors. Journal of Urology, 2020, 204, 259-259.	0.4	0
208	Reply by Authors. Journal of Urology, 2020, 204, 684-684.	0.4	0